{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:03:01Z","timestamp":1761487381760,"version":"build-2065373602"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T00:00:00Z","timestamp":1114473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The current Phase I\/II study assessed induction docetaxel\/carboplatin given weekly for 4 weeks, followed by weekly docetaxel\/carboplatin and concomitant boost radiotherapy (CB\u2010XRT) for locally advanced head and neck squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty patients with Stage III or IV (M0) disease of the oropharynx, supraglottic larynx, or hypopharynx were enrolled. Patients initially received docetaxel 20 mg\/m<jats:sup>2<\/jats:sup> and carboplatin area under the curve (AUC) 2 weekly \u00d7 4. Patients with stable (SD) or responding disease subsequently received dose\u2010escalated docetaxel (10\u201320 mg\/m<jats:sup>2<\/jats:sup> in sequential patient cohorts) and carboplatin AUC 1 weekly \u00d7 5 with CB\u2010XRT (1.8 gray [Gy] every day \u00d7 15 days, followed by 1.8\/1.5 Gy twice per day \u00d7 13 days).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>All patients were evaluable, and 15 patients (5 patients with Stage III disease, 10 patients with Stage IV disease) completed all planned therapy. The target docetaxel dose level of 20 mg\/m<jats:sup>2<\/jats:sup> weekly with radiotherapy was achieved with no dose\u2010limiting toxicities. The most frequent maximum toxicities during chemoradiotherapy were Grade 3 mucositis, dysphagia, and\/or pain. Primary site responses after induction included 4 patients with partial responses, 11 patients with SD, and 5 patients with disease progression. Fifteen patients (75%) continued to receive chemoradiotherapy, with 14 patients attaining a complete response (CR). Overall, a clinicopathologic neck CR after chemoradiotherapy was achieved in 9 of 10 patients. One patient had persistent primary disease and underwent salvage surgery, whereas another died of unrelated causes before neck assessment. Thirteen patients remain free of any disease event, with a median follow\u2010up of 15 months (range, 3\u201329 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>This regimen was feasible, safe, and particularly well tolerated. Early Phase II outcomes revealed promising activity in patients completing all treatment. Initial induction response results suggested that further investigation of this regimen with more aggressive induction therapy is warranted. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21085","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T14:16:58Z","timestamp":1114525018000},"page":"2534-2543","source":"Crossref","is-referenced-by-count":15,"title":["Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck"],"prefix":"10.1002","volume":"103","author":[{"given":"David L.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bevan","family":"Yueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raylene","family":"Canby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raelene","family":"Buelna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.838"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90011-4"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2081"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3339"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058908"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1672"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200106000-00003"},{"key":"e_1_2_5_9_2","first-page":"2305","article-title":"Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study","volume":"19","author":"Koukourakis MI","year":"1999","journal-title":"Anticancer Res."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10873"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601471"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3503"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11063"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.006"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.026"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00663-5"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870801)60:3<301::AID-CNCR2820600306>3.0.CO;2-V"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-198811000-00011"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30412-X"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1512"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.128.3.324"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1961"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1405"},{"key":"e_1_2_5_26_2","first-page":"506","article-title":"A phase I\/II trial of docetaxel and concomitant boost radiation therapy for patients with squamous cell cancer of the head and neck following induction chemotherapy","volume":"22","author":"Tishler R","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01690-X"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10038"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14361-9"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21085","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:03:52Z","timestamp":1760277832000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,2]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,15]]}},"alternative-id":["10.1002\/cncr.21085"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21085","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2005,6,2]]}}}